Last reviewed 2026-04-19 · How we verify

NDX-3315 and NDX-3324

NexEos Diagnostics, Inc. · Phase 2 active Small molecule

NDX-3315 and NDX-3324 is a Small molecule drug developed by NexEos Diagnostics, Inc.. It is currently in Phase 2 development.

At a glance

Generic name	NDX-3315 and NDX-3324
Sponsor	NexEos Diagnostics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NDX-3315 and NDX-3324 CI brief — competitive landscape report
NDX-3315 and NDX-3324 updates RSS · CI watch RSS
NexEos Diagnostics, Inc. portfolio CI

Frequently asked questions about NDX-3315 and NDX-3324

What is NDX-3315 and NDX-3324?

NDX-3315 and NDX-3324 is a Small molecule drug developed by NexEos Diagnostics, Inc..

Who makes NDX-3315 and NDX-3324?

NDX-3315 and NDX-3324 is developed by NexEos Diagnostics, Inc. (see full NexEos Diagnostics, Inc. pipeline at /company/nexeos-diagnostics-inc).

What development phase is NDX-3315 and NDX-3324 in?

NDX-3315 and NDX-3324 is in Phase 2.

Manufacturer: NexEos Diagnostics, Inc. — full pipeline
Compare: NDX-3315 and NDX-3324 vs similar drugs
Pricing: NDX-3315 and NDX-3324 cost, discount & access